Morgan Stanley
INTS icon

Morgan Stanley’s Intensity Therapeutics INTS Stock Holding History

Morgan Stanley’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82 Hold
20
– – ﹤0.01% 7982
2026
Q1 		$118 Hold
20
– – ﹤0.01% 7767
2025
Q4 		$205 Hold
20
– – ﹤0.01% 7626
2025
Q3 		$121 Hold
20
– – ﹤0.01% 7657
2025
Q2 		$154 Hold
20
– – ﹤0.01% 7603
2025
Q1 		$985 Hold
20
– – ﹤0.01% 7282
2024
Q4 		$880 Hold
20
– – ﹤0.01% 7290
2024
Q3 		$1.91K Hold
20
– – ﹤0.01% 7140
2024
Q2 		$2.45K Buy
+20
New +$2.27K ﹤0.01% 7030

Other funds holding INTS

KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Morgan Stanley's INTS Position: Q2 2026 in Review

Morgan Stanley held its Intensity Therapeutics (INTS) position steady in Q2 2026 at 20 shares worth $82. The position accounts for ﹤0.01% of the portfolio, ranked #7982.

Morgan Stanley first reported a position in INTS in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.45K in Q2 2024. 14 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

  • Morgan Stanley held 20 shares of Intensity Therapeutics worth $82 as of Q2 2026.
  • Morgan Stanley left its Intensity Therapeutics share count unchanged in Q2 2026.
  • Intensity Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7982 holding.
  • Morgan Stanley first reported a position in Intensity Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Morgan Stanley's Intensity Therapeutics position peaked at $2.45K in Q2 2024.
  • 14 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.